Chong Kun Dang Voluntarily Halts Phase 3 Clinical Trial of 'Nafabaltan' COVID-19 Treatment
[Asia Economy Reporter Lee Jung-yoon] Chong Kun Dang announced on the 1st that it has voluntarily discontinued the Phase 3 clinical trial of Napabeltan injection.
This is a Phase 3 clinical trial to evaluate the efficacy and safety of CKD-314 (Napabeltan injection) in patients diagnosed with COVID-19 pneumonia who were hospitalized.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- 2030s Prefer Temples, 5060s Choose Art Museums... Data Reveals Diverging Travel Preferences
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "Due to the decrease in COVID-19 incidence and the reduced progression rate to severe cases as a result of widespread vaccination, there are difficulties in conducting the clinical trial," adding, "Therefore, a change in development strategy is inevitable, and considering the opinions of COVID-19 experts and the overall situation, we have decided to discontinue this clinical trial."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
